SCHEMBL4271697

SCHEMBL4271697

O=C(c1ccccc1)c1ccccc1Nc1nc2sccc2c(=O)o1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ELANE P08246 3/20 0.48
C1R P00736 11/20 0.42
ALDH1A1 P00352 4/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.37
USP2 O75604 1/20 0.37
LMNA P02545 1/20 0.37
GLA P06280 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PIM1 P11309 1/20 0.37
CSNK2B P67870 1/20 0.37
CSNK2A1 P68400 1/20 0.37
PIM2 Q9P1W9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4393365 0.84 ELANE (0.46) ELANEC1RALDH1A1NPC1RAB9A
SCHEMBL4263020 0.84 ELANE (0.50) ELANEALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL4260518 0.78 ELANE (0.61) ELANEC1RALDH1A1NPC1RAB9A
SCHEMBL4258107 0.76 ELANE (0.49) ELANEC1RALDH1A1NPC1RAB9A
SCHEMBL4262925 0.76 ELANE (0.49) ELANEC1RALDH1A1NPC1RAB9A
SCHEMBL13891523 0.75 ELANE (0.53) ELANEALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL4266419 0.74 ELANE (0.48) ELANEALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL4264565 0.73 ELANE (0.51) ELANEC1RALDH1A1NPC1RAB9A
SCHEMBL4259315 0.73 ELANE (0.51) ELANEC1RALDH1A1NPC1RAB9A
SCHEMBL4261317 0.73 ELANE (0.46) ELANEALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1446125-B1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LTD (GB) 2009-04-29 EP claimed
US-20090029978-A1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LIMITED (GB) 2009-01-29 US claimed
US-7407954-B2 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity ALIZYME THERAPEUTICS LIMITED (GB) 2008-08-05 US claimed
US-20050075336-A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity NORGINE B.V. (NL) 2005-04-07 US claimed
EP-1446125-B1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LTD (GB) 2009-04-29 EP disclosed
US-20090029978-A1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LIMITED (GB) 2009-01-29 US disclosed
US-7407954-B2 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity ALIZYME THERAPEUTICS LIMITED (GB) 2008-08-05 US disclosed
US-20050075336-A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity NORGINE B.V. (NL) 2005-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075336-A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity LPL, LIPE, LIPC ELANE 282/4885C1R 3110/4885ALDH1A1 281/4885
US-20090029978-A1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY LPL, LIPE, LIPC ELANE 282/4885C1R 3110/4885ALDH1A1 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.